Cytokinetics, Incorporated - Common Stock (CYTK)

51.65
-1.52 (-2.86%)
NASDAQ · Last Trade: Nov 17th, 8:03 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Cytokinetics Touts MYQORZO Launch Momentum, Plans New FDA Filingmarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives said the company is seeing momentum in the launch of heart drug MYQORZO and is preparing to seek U.S. approval for its use in a second form of hypertrophic cardiomyopathy. Speaking at the UBS Biopharma Conference, President and CEO Robert Blum also announced th
Via MarketBeat · November 17, 2026
Cytokinetics’ MYQORZO Gains Ground as Company Plans Push Into New Heart-Disease Marketmarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives said the launch of its heart drug MYQORZO is gaining prescribers and market share as the company prepares regulatory submissions that could expand use of aficamten, the drug’s active ingredient. Chief Business Officer Isaac Ciechanover said revenue rose 76% fro
Via MarketBeat · November 16, 2026
Cytokinetics (CYTK) Q3 2026 Earnings Call Transcriptfool.com
MYQORZO sales climbed sharply as prescriber adoption broadened beyond specialists.
Via The Motley Fool · November 5, 2026
Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launchchartmill.com
Via Chartmill · August 6, 2026
Cytokinetics Inc. (NASDAQ:CYTK) Scores Strong Setup Quality for a Potential Breakoutchartmill.com
Via Chartmill · April 23, 2026
Cytokinetics Q3 Earnings Call Highlightsmarketbeat.com
Cytokinetics (NASDAQ:CYTK) reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand the treatment’s use. President and CEO Robert Blum said the launch, nearly nine months in, continue
Via MarketBeat · November 4, 2026
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conferencemarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure. Isaac Ciecha
Via MarketBeat · September 25, 2026
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 10.3% on an annualized basis producing an average annual return of 23.89%. Currently, Cytokinetics has a market capitalization of $10.16
Via Benzinga · September 11, 2026
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Todaybenzinga.com
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 21.28%. Currently, Cytokinetics has a market capitalization of $10.34
Via Benzinga · August 28, 2026
Cytokinetics’ Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCMmarketbeat.com
Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise cap
Via MarketBeat · August 28, 2026
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700fool.com
Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.
Via The Motley Fool · August 22, 2026
Cytokinetics (CYTK) Q2 2026 Earnings Call Transcriptfool.com
MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.
Via The Motley Fool · August 13, 2026
Cytokinetics Q2 Earnings Call Highlightsmarketbeat.com
Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM. Chief Executive Officer Robert Blum said t
Via MarketBeat · August 6, 2026
Here's How Much $100 Invested In Cytokinetics 10 Years Ago Would Be Worth Todaybenzinga.com
Cytokinetics (NASDAQ:CYTK) has outperformed the market over the past 10 years by 7.02% on an annualized basis producing an average annual return of 20.46%. Currently, Cytokinetics has a market capitalization of $10.71
Via Benzinga · August 5, 2026
Prediction: U.S. Small-Cap Stocks Will Beat Large Caps for 10 Yearsfool.com
If you want to lock in future gains from today's small-cap stocks, these two ETFs could be good options.
Via The Motley Fool · July 21, 2026
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%fool.com
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.
Via The Motley Fool · July 14, 2026
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praisemarketbeat.com
Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS program and recent clinical data in hypertrophic cardiomyopathy during a discussion hosted by RBC Capi
Via MarketBeat · May 22, 2026
Cytokinetics (CYTK) Q1 2026 Earnings Transcriptfool.com
Cytokinetics (CYTK) Q1 2026 Earnings Transcript
Via The Motley Fool · May 5, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · May 5, 2026
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potentialfool.com
This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.
Via The Motley Fool · March 23, 2026
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Resetfool.com
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Via The Motley Fool · March 21, 2026
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growthfool.com
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Via The Motley Fool · March 21, 2026
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cashfool.com
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
Via The Motley Fool · March 21, 2026
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filingfool.com
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.
Via The Motley Fool · March 21, 2026
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Yearfool.com
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Via The Motley Fool · March 20, 2026